Publications 2020
507.
Mokou M, Lygirou V, Angelioudaki I, Paschalidis N, Stroggilos R, Frantzi M, Latosinska A, Hoffmann MJ, Mischak H, Vlahou A
Drug repurposing of bladder cancer driven by patients’ proteomic signatures
Urologic Oncology: Seminars and Original Investigations 2020, 38(12): 897-898.
506.
Magalhães P, Zürbig P, Mischak H, Schleicher E.
Urinary fetuin-A peptides as a new marker for impaired kidney function in patients with type 2 diabetes
Clin Kidney J. 2020, 14(1):269-276.
505.
Fédou C, Breuil B, Golovko I, Decramer S, Magalhães P, Muller F, Dreux S, Zürbig P, Klein J, Schanstra JP, Buffin-Meyer B.
Comparison of the amniotic fluid and fetal urine peptidome for biomarker discovery in renal developmental disease
Sci Rep. 2020, 10(1):21706.
504.
Frantzi M, Latosinska A, Mokou M, Mischak H, Vlahou A.
Drug repurposing in oncology
Lancet Oncol. 2020, 21(12):e543.
503.
Bannaga AS, Metzger J, Kyrou I, Voigtländer T, Book T, Melgarejo J, Latosinska A, Pejchinovski M, Staessen JA, Mischak H, Manns MP, Arasaradnam RP.
Discovery, validation and sequencing of urinary peptides for diagnosis of liver fibrosis-A multicentre study
..EBioMedicine. 2020, 62:103083. Epub 2020 Nov 5.
502.
Mokou M, Lygirou V, Angelioudaki I, Paschalidis N, Stroggilos R, Frantzi M, Latosinska A, Bamias A, Hoffmann MJ, Mischak H, Vlahou A.
A Novel Pipeline for Drug Repurposing for Bladder Cancer Based on Patients' Omics Signatures
Cancers (Basel). 2020, 12(12):3519.
501.
Wendt R, Kalbitz S, Lübbert C, Kellner N, Macholz M, Schroth S, Ermisch J, Latosisnka A, Arnold B, Mischak H, Beige J, Metzger J.
Urinary Proteomics Associates with COVID-19 Severity: Pilot Proof-of-Principle Data and Design of a Multicentric Diagnostic Study
Proteomics. 2020, 20(24):e2000202.
500.
Klein J, Caubet C, Camus M, Makridakis M, Denis C, Gilet M, Feuillet G, Rascalou S, Neau E, Garrigues L, Thillaye du Boullay O, Mischak H, Monsarrat B, Burlet-Schiltz O, Vlahou A, Saulnier-Blache JS, Bascands JL, Schanstra JP.
Connectivity mapping of glomerular proteins identifies dimethylaminoparthenolide as a new inhibitor of diabetic kidney disease
Sci Rep. 2020, 10(1):14898.
499.
Frantzi M, Hupe MC, Merseburger AS, Schanstra JP, Mischak H, Latosinska A.
Omics Derived Biomarkers and Novel Drug Targets for Improved Intervention in Advanced Prostate Cancer
Diagnostics (Basel). 2020, 10(9):658.
498.
Latosinska A, Davalieva K, Makridakis M, Mullen W, Schanstra JP, Vlahou A, Mischak H, Frantzi M.
Molecular Changes in Tissue Proteome during Prostate Cancer Development: Proof-of-Principle Investigation
Diagnostics (Basel). 2020, 10(9):655.
497.
Wendt R, He T, Latosinska A, Siwy J, Mischak H, Beige J.
Proteomic characterization of obesity-related nephropathy
Clin Kidney J. 2020, 13(4):684-692.
496.
Campbell RT, Jasilek A, Mischak H, Nkuipou-Kenfack E, Latosinska A, Welsh PI, Jackson CE, Cannon J, McConnachie A, Delles C, McMurray JJV.
The novel urinary proteomic classifier HF1 has similar diagnostic and prognostic utility to BNP in heart failure
ESC Heart Fail. 2020, 7(4):1595-1604. Epub 2020 May 8.
495.
He T, Siwy J, Metzger J, Mullen W, Mischak H, Schanstra JP, Zürbig P, Jankowski V.
Associations of urinary polymeric immunoglobulin receptor peptides in the context of cardio-renal syndrome
Sci Rep. 2020, 10(1):8291.
494.
Mischak H.
Datasharing: Obsolete? Impossible in times of GDPR ? Or mandatory in science?!
Eur J Clin Invest. 2020, 50(8):e13244.
493.
Pejchinovski M, Mischak H.
Re-analysis of "Peptidomic analysis of cartilage and subchondral bone in OA patients"
Eur J Clin Invest. 2020, 50(8):e13240.
492.
Weeding E, Fava A, Buyon J, Belmont HM, Izmirly P, Clancy R, Monroy-Trujillo J, Fine D, Apruzzese W, Mischak H, Petri M.
0029: Urine proteomic classifiers predict renal histological activity and chronicity indices and may predict treatment response in lupus nephritis
Arthritis & Rheumatology. 2020;72(Suppl 10).
491.
Tofte N, Lindhardt M, Currie G, Frimodt-Møller M, von der Leyen H, Delles C, Mischak H, Rossing P, PRIORITY Investigators.
P1006: Impact of glucose-lowering and antihypertensive medications on development of microalbuminuria in subjects with type 2 diabetes and normoalbuminuria in the PRIORITY study
Nephrology Dialysis Transplantation 2020, 35(Suppl 3):iii1328.
490.
Stroggilos RS, Mokou M, Latosinska A, Makridakis M, Lygirou V, Mavrogeorgis E, Drekolias D, Frantzi M, Mullen W, Fragkoulis C, Stasinopoulos K, Papadopoulos G, Stathouros G, Ntoumas K, Mischak H, Zoidakis J, Vlahou A.
B18:Molecular classification of NMIBC based on protein abundance
Clinical Cancer Research. 2020;26(15 Suppl):B18.
489.
Petra E, He T, Latosinska A, Stroggilos R, Mischak H, Vlahou A.
P0650: Urine peptidome analysis in heart failure, chronic kidney disease and cardiorenal syndrome towards the definition of disease-specific markers
Nephrology Dialysis Transplantation 2020, 35(Suppl. 3):gfaa143.P0650.
488.
Pejchinovski M, Marx D, Metzger J, Olagne J, Caillard S, Moulin B, Mullen W, Mischak H, Naesens M, Anglicheau D.
TO006: Non-invasive diagnosis of BK virus-associated nephropathy using urinary proteomics in kidney allograft patients
Nephrology Dialysis Transplantation. 2020;35(Suppl 3):gfaa141.TO006.
487.
He T, Schanstra J, Siwy J, Beige J, Latosinska A, Mischak H.
P0652: Thymosin beta 4 and kidney function: an inverse relationship?
Nephrology Dialysis Transplantation 2020, 35(Suppl 3):gfaa142.P0652.
486.
He T, Raad J, Beige J, Mischak H.
P1457: Comparison of peptidomes between urine, plasma, and hemodialysis fluid indicates selectivity in renal peptide processing
Nephrology Dialysis Transplantation. 2020;35(Suppl. 3):gfaa142.P1457.
485.
He T, Beige J, Siwy J, Wendt R, Latosinska A, Mischak H.
P0651: Proteomic characterization of obesity-related nephropathy
Nephrology Dialysis Transplantation 2020, 35(Suppl. 3):gfaa142.P0651.
484.
Lindhardt M, Tofte N, Currie G, Frimodt-Møller M, von der Leyen H, Delles C, Mischak H, Rossing P, for the PRIORITY Investigators.
MO048 – Multicentre prospective validation of the urinary peptidome-based classifier CKD273 as a predictor of renal function decline in subjects with type 2 diabetes
Nephrology Dialysis and Transplantation 2020, 35(Suppl3):gfaa140.MO048.
483.
Curovic VR, Magalhães P, Hansen T, Mischak H, Rossing P.
PO0981 Association Between the Urinary Proteome and Diabetic Retinopathy in the DIRECT-Protect 1 and 2 Trials
Journal of the American Society of Nephrology 2020, 31(10S):336.
482.
He T, Beige J, Siwy J, Golovko I, Pejchinovski M, Metzger J, Mullen W, Vlahou A, Mischak H.
P0106: Urine complement fragments are associated with kidney function and disease etiology
Nephrology Dialysis Transplantation 2020, 35(Suppl3):gfaa142.P0106.
481.
Tofte N, Lindhardt M, Adamova K, Bakker SJL, Beige J, Beulens JWJ, Birkenfeld AL, Currie G, Delles C, Dimos I, Francová L, Frimodt-Møller M, Girman P, Göke R, Havrdova T, Heerspink HJL, Kooy A, Laverman GD, Mischak H, Navis G, Nijpels G, Noutsou M, Ortiz A, Parvanova A, Persson F, Petrie JR, Ruggenenti PL, Rutters F, Rychlík I, Siwy J, Spasovski G, Speeckaert M, Trillini M, Zürbig P, von der Leyen H, Rossing P; PRIORITY investigators.
Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial
Lancet Diabetes Endocrinol. 2020, 8(4):301-312. Epub 2020 Mar 2.
480.
Makridakis M, Kontostathi G, Petra E, Stroggilos R, Lygirou V, Filip S, Duranton F, Mischak H, Argiles A, Zoidakis J, Vlahou A.
Multiplexed MRM-based protein quantification of putative prognostic biomarkers for chronic kidney disease progression in plasma
Sci Rep. 2020, 10(1):4815.
479.
Frantzi M, Gonez-Gomez E, Mischak H.
Noninvasive biomarkers to guide intervention: toward personalized patient management in prostate cancer
Expert Review of Precision Medicine and Drug Development 2020, 5(5):383-400.
478.
Buffin-Meyer B, Tkaczyk M, Stańczyk M, Breuil B, Siwy J, Szaflik K, Talar T, Wojtera J, Krzeszowski W, Decramer S, Klein J, Schanstra JP.
A single-center study to evaluate the efficacy of a fetal urine peptide signature predicting postnatal renal outcome in fetuses with posterior urethral valves
Pediatr Nephrol. 2020, 35(3):469-475. Epub 2019 Nov 7.
477.
Nkuipou-Kenfack E, Latosinska A, Yang WY, Fournier MC, Blet A, Mujaj B, Thijs L, Feliot E, Gayat E, Mischak H, Staessen JA, Mebazaa A, Zhang ZY; French and European Outcome Registry in Intensive Care Unit Investigators.
A novel urinary biomarker predicts 1-year mortality after discharge from intensive care
Crit Care. 2020, 24(1):10.
476.
Voigtländer T, Metzger J, Husi H, Kirstein MM, Pejchinovski M, Latosinska A, Frantzi M, Mullen W, Book T, Mischak H, Manns MP.
Bile and urine peptide marker profiles: access keys to molecular pathways and biological processes in cholangiocarcinoma
J Biomed Sci. 2020, 27(1):13.
475.
Bruno RM, Mischak H, Persu A.
Multi-omics applied to fibromuscular dysplasia: first steps on a new research avenue
Cardiovasc Res. 2020, 116(1):4-5.
474.
Siwy J, Ahonen L, Magalhães P, Frantzi M, Rossing P.
Metabolomic and Proteomic Techniques for Establishing Biomarkers and Improving Our Understanding of Pathophysiology in Diabetic Nephropathy
Methods Mol Biol. 2020, 2067:287-306.
473.
Stroggilos R, Mokou M, Latosinska A, Makridakis M, Lygirou V, Mavrogeorgis E, Drekolias D, Frantzi M, Mullen W, Fragkoulis C, Stasinopoulos K, Papadopoulos G, Stathouros G, Lazaris AC, Makrythanasis P, Ntoumas K, Mischak H, Zoidakis J, Vlahou A.
Proteome-based classification of Nonmuscle Invasive Bladder Cancer
Int J Cancer. 2020, 146(1):281-294. Epub 2019 Jul 26.